Business impact of amendments to the Pharmaceuticals and Medical Devices Act and other laws, and deregulation
First written in FY2019. 10 of 11 entries say "Restated". Latest entry: FY2027-H1.
The whole theme swung hardest in 2026: 4 of 9 companies on the "Worse" side.
13 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「No new business or other risks arose during the six months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It was stated that there had been no material changes regarding the risk of amendments to laws and regulations and deregulation affecting business plans and performance. - FY2025-H1RestatedAnnual report
「No new business or other risks arose during the interim consolidated accounting period. In addition, there were no significant changes to the business and other risks described in the previous fiscal year's Annual Securities Report.」
It was stated that there had been no material changes regarding the risk of amendments to laws and regulations and deregulation affecting business plans and performance. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding the risk of amendments to laws and regulations and deregulation affecting business plans and performance. - FY2023RestatedAnnual report
「If deregulation advances further and competition with other industries intensifies, the Group's business plans and performance may be affected.」
Continues to identify the risk of business impacts from amendments to laws and regulations and deregulation concerning pharmaceuticals and other products. - FY2023-Q2RestatedAnnual report
「No new business or other risks arose during the six months ended 30 September. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding the risk of business impacts from amendments to laws and regulations and deregulation. - FY2022RestatedAnnual report
「Amendments to these laws and regulations may affect store operations and other activities. If deregulation advances further and competition with other industries intensifies, the Group's business plans and performance may be affected.」
Continues to identify the risk of business impacts from amendments to laws and regulations concerning pharmaceuticals, alcoholic beverages and food products, and deregulation of pharmaceutical sales. - FY2022-Q2RestatedAnnual report
「During the second quarter consolidated cumulative period, there were no newly arising business or other risks. In addition, there were no significant changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It was stated that there had been no material changes regarding the risk of business impacts from amendments to laws and regulations and deregulation. - FY2022-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It was stated that there had been no material changes regarding the risk of business impacts from amendments to laws and regulations and deregulation. - FY2021RestatedAnnual report
「Amendments to these laws and regulations may affect store operations and other activities. If deregulation advances further and competition with other industries intensifies, the Group's business plans and performance may be affected.」
Continues to identify the risk of business impacts from amendments to laws and regulations concerning pharmaceuticals, alcoholic beverages and food products, and deregulation of pharmaceutical sales. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding the risk of amendments to laws and regulations and deregulation affecting business plans and performance. - FY2019First statedAnnual report
「Amendments to these laws and regulations may affect store operations and other activities. If deregulation advances further and competition with other industries intensifies, the Group's business plans and performance may be affected.」
Identified as business risks the licensing and approval systems for pharmaceuticals, alcoholic beverages and food products, among others, amendments to laws and regulations, and deregulation including online sales of over-the-counter drugs.